HilleVax Q1 2023 Earnings Report

HilleVax reported financial results for Q1 2023 and highlighted progress on HIL-214 program.

Key Takeaways

HilleVax reported a net loss of $26.9 million for the first quarter of 2023, with cash and cash equivalents totaling $260.5 million as of March 31, 2023. The company's research and development expenses increased to $23.2 million due to the advancement of the HIL-214 program.

Completed enrollment of over 3,000 subjects in the NEST-IN1 clinical trial.

Announced the appointment of Nanette Cocero, Ph.D., MBA, to its Board of Directors.

Expects topline safety and clinical efficacy data from NEST-IN1 in the first quarter of 2024.

Cash and cash equivalents totaled $260.5 million as of March 31, 2023.

EPS

-$0.71

Previous year: -$10.1

-92.9%

Research and Development Expenses

$23.2M

General and Administrative Expenses

$5.8M